325results about How to "Reduce allergic reactions" patented technology

The invention discloses a mask solution. The mask solution contains a moisturizer, wherein the moisturizer is prepared from sodium hyaluronate, trehalose, sodium polyglutamate, betaine, tremella polysaccharide and glyceryl polymethacrylate. The mask solution disclosed by the invention is capable of durably and deeply moisturizing the skin, is good in mildness, is also suitable for skin sensitive persons, is natural and non-toxic, is mild and non-irritant, cannot damage the skin after long-term use, has an obvious effect in improving the skin, and is beneficial for enabling the skin to restore elasticity and be glossy.

The invention discloses a muting sensitive lactalbumin hydrolysate and a preparation method thereof. The method mainly comprises the following steps: dissolving condensed whey protein in the water, then carrying out denaturation under high temperature, carrying out hydrolysis by using the protamex composed of alkali protease, papain and flavourzyme, treating the lactalbumin hydrating solution with desalinization and drying to obtain the lactalbumin hydrolysate of the invention. The lactalbumin hydrolysate of the invention has high suppression ratio of Beta-lactoglobulin and Alpha- lactalbumin, can reduce or eliminate cow milk allergic reaction; furthermore, the lactalbumin hydrolysate can also produce other active materials, thus also having the functions of promoting immunity, being easy to digest and absorb and reducing blood pressure; and the lactalbumin hydrolysate has high security and no side effect, bitter taste or other bad flavors.

Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.

The invention discloses a film coating agent for wound surface treatment and a preparation method of the film coating agent. The film coating agent comprises chitosan, a film-forming material, a plasticizer and a solvent, wherein the plasticizer is glycerin with the amount accounting for 2-15% of the total weight of the film coating agent. The film coating agent has the advantages that the film coating agent is better in antibacterial effect, more convenient to use and better in waterproofness, is not limited by shapes and sizes of skin wound surfaces, does not affect normal limb movement and the like.

The invention relates to an efficient mycoplasma hyopneumoniae culture medium and a preparation method thereof, and belongs to the technical field of veterinary biology. The efficient mycoplasma hyopneumoniae culture medium comprises an A liquid and a B liquid mainly consisting of MEM, yeast leaching powder, tryptone, glucose, inorganic salt and the like. The prepared culture medium of the invention has the main advantages of low serum content which is only 10%-15%, while the serum content in common culture medium is 20% even more. The culture medium prepared by the low serum relieves the pig allergic to the stress reaction, meanwhile gives consideration to the biosafety of animals. Besides the valence of the semi-finished bacterial solution prepared by the method is up to 109CCU/ml, which is much higher than the culture medium prepared by the common technology.

The invention belongs to the technical field of medicines and discloses melittin complex nanoparticles for oral administration and a preparation method thereof. Water-soluble melittin and an amphiphilic substance are dissolved into a hydrosolvent A to form a hydrophobic protein ion pairing complex; the complex and a suitable polymer material are dissolved into a nonaqueous solvent B; an emulsion solvent diffusion method in a liquid phase is adopted to wrap the complex into the polymer material; and microparticles with the particle diameter between 10 and 1000nm are formed after the solvent is volatilized. The hydrosolvent A is distilled water, double distilled water, deionized water, physiological saline, or a phosphate buffer solution or an acetate buffer solution or a Tris buffer solution with the pH value of between 1 and 11; and the nonaqueous solvent B is a single or mixed solvent of alcohol, acetone, ethyl acetate, methylene dichloride, chloroform and dimethyl sulfoxide. The complex has high fat solubility, and the encapsulation rate of the nanoparticles is more than 90 percent. The preparation process is mild and can assure the biological activity of medicines. The preparation method is suitable to prepare oral administration preparations.

The invention discloses an omeprazole sodium freeze-dried powder injection and a preparation method thereof. The omeprazole sodium freeze-dried powder injection contains an active ingredient, namely, omeprazole sodium monohydrate, and auxiliary materials, namely, calcium disodium edetate and sodium hydroxide. The preparation method of the omeprazole sodium freeze-dried powder injection is characterized by comprising the following steps: weighing the calcium disodium edetate of prescription amount and dissolving the calcium disodium edetate in water for injection, stirring, dissolving, and regulating pH value to 10.0-12.0 by using 10% of sodium hydroxide solution; weighing omeprazole sodium of the prescription amount and adding the omeprazole sodium in the mixture, stirring at room temperature for dissolution, supplementing and adding the water for injection to full amount; adding active carbon, stirring at room temperature for decoloration and endotoxin removal, conducting rough filtration to remove carbon firstly, and then conducting refining filtration by using a filter membrane of 0.22 Mum; taking refining filtrate to test intermediate, conducting encapsulation after meeting requirements; and freeze-drying and unboxing, thus obtaining the omeprazole sodium freeze-dried powder injection. The freeze-drying technology of the omeprazole sodium freeze-dried powder injection takes temperature below minus 40 DEG C as pre-freezing temperature; after pre-freezing for at least two hours, sublimation is started, wherein the sublimation temperature is 5-12 DEG C, the sublimation time is over 14 hours; and then drying is conducted for over 2 hours at the temperature of 20-35 DEG C. Unboxing is carried out after a stopper is added and a cover is put in place, thus obtaining the finished product of the omeprazole sodium freeze-dried powder injection.

The invention provides a self-emulsifying medical composition for delivering taxane medicaments and a preparation method thereof. The self-emulsifying medical composition is transparent liquid, comprises an effective dose of taxane compound, an oil component, a surface active agent and alcohol and preferentially comprises lactic acid, wherein the surface active agent consists of phospholipid and polyoxyethylenated castor oil. After the self-emulsifying composition is added to a glucose injection, the composition can self-emulsify into micro emulsion the mean grain size of which is 50-300nm, and the micro emulsion can stabilize for more than 12 hours at room temperature. The preferential taxane compound in the invention is taxol.

A novel protein allergen Der p VII of Dennatophagoides pteronyssinus is described. A cDNA clone encoding Der p VII was isolated from a lambda gt11 library of D. pteronyssinus cDNA. The nucleic acid sequence of der p VII encodes a 198 residue mature processed protein having a predicted molecular weight of 22,177 daltons. Der p VII protein may be used as the active ingredient in therapeutic composition for the treatment of sensitivity to house dust mites. The protein may also be used in methods of diagnosing such sensitivity.

A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDRl, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

The invention mainly relates to a Shuanghuanglian liquid preparation and a method for measuring the content thereof. The Shuanghuanglian liquid preparation mainly comprises scutelloside, forsythin, chlorogenic acid, and the like, and the adverse reaction thereof is mainly shown in anaphylactic shock, erubescent skin and exanthemata, etc. The invention provides the Shuanghuanglian liquid preparation containing proper chlorogenic acid, scutelloside, forsythin and other effective components, and not only has ideal therapeutic effect, but also reduces the occurrence of the anaphylactic reaction. The invention also provides the method for measuring the content of the Shuanghuanglian liquid preparation; during the application of the measurement method of the invention, only one moving phase is needed to simultaneously measure the content of the five effective components, i.e. the scutelloside, the forsythin, the chlorogenic acid, luteoloside and wogonin. The method not only obviously improves the measurement efficiency, but also effectively reduces the measurement cost.

The present invention relates to a sarcopeptidoglucoside powder injection and its preparation method. It is formed from polypeptide, hydroxanthine and excipient. Said invention adopts the modern biological extraction technique to prepare sarcopeptidoglucoside solution, and utilizes the modern low-temp. freeze-drying preparation technique to obtain the invented sterile freeze-dried powder injection. When it is used, it can be dissolved by injection water or infusion fluid, then can be injected. Said invention has good stability, long storage time and high safety, etc.

The invention relates to a goat milk kefir produced with polymerized lactalbumin as a thickener, and belongs to the technical field of functional foods. The goat milk kefir is produced through coordinating fresh goat milk as liquid raw milk with sugar, polymerized lactalbumin, low methoxyl pectin and a kefir starter. The goat milk kefir product is produced through the following steps: mixing sugar with low methoxyl pectin in advance, adding the obtained mixture to the liquid raw milk; adding a polymerized lactalbumin solution; stirring and heating the above solution to 80-90DEG C, carrying out heat insulation for 10-20min for sterilization, and carrying out ice bath cooling to room temperature; and adding the kefir starter, stirring above materials until uniformity, and fermenting the obtained mixture at 25-35DEG C for 8-14h. The product has the advantages of high content of proteins, low content of fats, stable curd state, uniform structure, moderate viscosity, unique flavor and various health functions; and a production technology of the goat milk kefir has the advantages of few raw material components, easy operation, energy saving and low cost, and is a simple production processing mode.

The invention provides a combined live vaccine for preventing porcine reproductive and respiratory syndrome and pseudorabies, and a preparation method and application thereof. According to the invention, no immunosuppression occurs between two vaccines of the combined live vaccine; compared with each single vaccine, the combined live vaccine has no obvious difference in security, immunogenicity, immunity duration and immuno-protective effects and has remarkable immuno-protective effects on preventing porcine reproductive and respiratory syndrome and pseudorabies.

The invention discloses skin allergy relieving liquid and a preparation method and application for the skin allergy relieving liquid, and belongs to the field of cosmetics. The skin allergy relieving liquid is made from six types of plant materials including total chrysanthemum indicum plants, wild hedera helix stems/leaves, witch hazel stems/leaves, chamomile flowers/leaves, golden camellia leaves and kalanchoe pinnata stems/leaves. The preparation method includes steps of cleaning, grinding, extraction by the aid of hot water, adsorption by the aid of kaolin, still standing, pressure filtration, ultra filtration and the like so as to obtain refined complex extract. The skin allergy relieving liquid, the preparation method and the application have the advantages that the skin allergy relieving liquid is a pure-plant preparation and is unique in formulation, synergistic effects can be realized by beneficial factors in the six types of plant materials, accordingly, immune functions of human bodies can be effectively regulated, the microvascular circulation of the skins of the human bodies can be improved, inflammation diminishing and itching relieving effects can be realized, the metabolism of the skins of the human bodies can be promoted, allergic sources can be inhibited and eliminated, and allergic reaction can be relieved; the skin allergy relieving liquid is simple in production process, high in operability and convenient to use, not only can be used as spray, but also can be used as emulsion to be directly applied to the skins of the human bodies.

Compositions suitable for reducing symptoms of an allergic response to environmental allergens comprising molecules that specifically inhibit the ability of the allergen to bind to mast cells in an animal predisposed to having an allergic response to the allergen and methods for reducing such symptoms comprising contacting a source of the environmental allergen with such compositions. Kits, packages, medicaments, and means of communicating about the compositions and methods are also provided.

The invention discloses a composition with anti-allergy, anti-inflammatory and soothing effects as well as a preparation method and application thereof, and the composition comprises the following components in percentage by mass: 5-30% of lactobacillus/soybean milk fermentation product filtrate, 5-25% of kava extract, 0.5-5% of dipotassium glycyrrhizinate, 5-25% of oat kernel extract, 1-5% of glycosylglycerol and the balance of solvent. The composition provided by the invention achieves the effects of anti allergy, anti-inflammatory and soothing from the aspects of skin micro-ecological barrier recovery, skin physical barrier recovery, nerve calming and soothing, inflammation inhibition and the like.